Qualigen Therapeutics Files 8-K on Officer/Director Changes
Ticker: AIXC · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financial-reporting
Related Tickers: QLGN
TL;DR
Qualigen Therapeutics (QLGN) filed an 8-K detailing board and officer changes, plus financial exhibits.
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on September 26, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the report being filed as of September 29, 2025.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate governance and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- September 26, 2025 (date) — Date of earliest event reported
- September 29, 2025 (date) — Date filed as of
- Delaware (jurisdiction) — State of incorporation
- Carlsbad, California (location) — Principal executive offices
FAQ
What specific items are covered under the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' section?
The filing indicates these topics are covered, but the specific details of departures, elections, appointments, and compensatory arrangements are not provided in this excerpt.
What is the significance of the 'Financial Statements and Exhibits' being included in this 8-K?
Including financial statements and exhibits means the company is providing supporting financial documentation alongside the corporate event disclosures.
When was Qualigen Therapeutics, Inc. formerly known as Ritter Pharmaceuticals Inc. and when did the name change occur?
The company was formerly known as Ritter Pharmaceuticals Inc., and the date of the name change was April 2, 2009.
What is the principal executive office address for Qualigen Therapeutics, Inc.?
The principal executive office is located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the SIC code for Qualigen Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Qualigen Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-29 06:04:19
Key Financial Figures
- $0.001 — ch registered Common stock (par value $0.001 per share) QLGN The Nasdaq Stock Ma
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-25-015846.txt ( ) — 198KB
- qlgn-20250926.xsd (EX-101.SCH) — 3KB
- qlgn-20250926_lab.xml (EX-101.LAB) — 33KB
- qlgn-20250926_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 29, 2025 By: /s/ Kevin A. Richardson II Kevin A. Richardson II Chief Executive Officer